Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Oncternal Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GTU2 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GTU2 underperformed the German Biotechs industry which returned -4.1% over the past year.
Return vs Market: GTU2 underperformed the German Market which returned 8.1% over the past year.
Price Volatility Vs. Market
How volatile is Oncternal Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Oncternal Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GTU2's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GTU2's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GTU2 is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: GTU2 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GTU2's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GTU2 is overvalued based on its PB Ratio (4.1x) compared to the DE Biotechs industry average (2.2x).
How is Oncternal Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oncternal Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Oncternal Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Oncternal Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Oncternal Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: GTU2 is currently unprofitable.
Growing Profit Margin: GTU2 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GTU2's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GTU2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GTU2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.4%).
Return on Equity
High ROE: GTU2 has a negative Return on Equity (-185.87%), as it is currently unprofitable.
How is Oncternal Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: GTU2's short term assets ($16.6M) exceed its short term liabilities ($7.3M).
Long Term Liabilities: GTU2's short term assets ($16.6M) exceed its long term liabilities ($53.0K).
Debt to Equity History and Analysis
Debt Level: GTU2 is debt free.
Reducing Debt: GTU2 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GTU2 has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: GTU2 is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.
What is Oncternal Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GTU2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GTU2's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GTU2's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GTU2's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GTU2's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Breitmeyer (66 yo)
Dr. James B. Breitmeyer, also known as Jim, M.D., Ph.D., serves as Director of Otonomy, Inc. since June 20, 2018. He serves as the Chief Executive Officer and President of Oncternal Therapeutics, Inc. Dr. ...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD1.12M) is above average for companies of similar size in the German market ($USD476.02K).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
|President||no data||US$1.12m||1.4% |
|General Counsel||1.58yrs||US$929.92k||0.26% |
|Chief Medical Officer||1yr||US$1.33m||no data|
|CFO, Treasurer & Secretary||3.25yrs||no data||0.24% |
|Chief Scientific Officer||0.92yr||no data||no data|
|Senior Vice President of Chemistry||1yr||no data||no data|
|Chief Business Officer||0.92yr||no data||no data|
Experienced Management: GTU2's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
|President||no data||US$1.12m||1.4% |
|Independent Director||1.58yrs||US$146.03k||0.0026% |
|Independent Director||1.58yrs||US$148.58k||0.050% |
|Independent Director||1.58yrs||US$148.30k||0.082% |
|Independent Chairman||1.58yrs||US$272.80k||no data|
|Scientific Advisor||no data||no data||no data|
|Independent Director||2.25yrs||US$143.77k||0.074% |
|Independent Director||0.67yr||US$89.71k||no data|
|Non-Independent Director||1.17yrs||US$484.31k||no data|
|Scientific Advisor||no data||no data||no data|
|Independent Director||2.58yrs||US$141.50k||no data|
Experienced Board: GTU2's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GTU2 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.6%.
Oncternal Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Oncternal Therapeutics, Inc.
- Ticker: GTU2
- Exchange: DB
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$56.168m
- Listing Market Cap: US$47.653m
- Shares outstanding: 19.92m
- Website: https://www.oncternal.com
Number of Employees
- Oncternal Therapeutics, Inc.
- 12230 El Camino Real
- Suite 300
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ONCT||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jun 2019|
|GTU2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2019|
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company’s product pipeline includes cirmtuzumab, a monoclonal anti ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/08 21:12|
|End of Day Share Price||2020/08/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.